| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803061101017 | 306110101 | CAPIBINE F.C.TAB 150MG/TAB BTx60 BLISTER PVC/PVDC/AL | 13.51 | 14.17 | 19.53 |
| 05/2018 | 2803061101024 | 306110102 | CAPIBINE F.C.TAB 150MG/TAB BTx60 BLISTER PVC/PE/PVDC/AL | 13.51 | 14.17 | 19.53 |
| 05/2018 | 2803061102014 | 306110201 | CAPIBINE F.C.TAB 500MG/TAB BTx120 BLISTER PVC/PVDC/AL | 79.78 | 83.69 | 106.46 |
| 05/2018 | 2803061102021 | 306110202 | CAPIBINE F.C.TAB 500MG/TAB BTx120 BLISTER PVC/PE/PVDC/AL | 79.78 | 83.69 | 106.46 |
For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Capecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, therefore a deficiency of this compound can inhibit cell division. Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis through the production of fraudulent RNA.
Readily absorbed through the GI tract (~70%)
45-60 minutes for capecitabine and its metabolites.
Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose.About 3% of the administered dose is excreted in urine as unchanged drug.